Showing results (61-70 of 88) with videos related to
Sort By:
Pageof 9
Blood Advances|November 23, 2021
Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric studySebastian Böttcher, Robby Engelmann, Georgiana Grigore, et al.European Journal of Haematology|December 9, 2015
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemiaChristian Maurer, Natali Pflug, Jasmin Bahlo, et al.Blood|February 2, 2022
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemiaHenriette Huber, Simone Edenhofer, Julia von Tresckow, et al.Blood|June 4, 2014
B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphomaVincent H J van der Velden, Patricia G Hoogeveen, Dick de Ridder, et al.Blood Advances|January 30, 2024
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, et al.Journal of Immunological Methods|October 27, 2019
Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS Canto II, Navios and BD FACS Lyric instrumentsHana Glier, Michaela Novakova, Jeroen Te Marvelde, et al.The Lancet. Oncology|May 15, 2016
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.Blood|April 15, 2024
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trialMoritz Fürstenau, Adam Giza, Jonathan Weiss, et al.The Lancet. Haematology|September 17, 2017
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 studyAnna Maria Fink, Jasmin Bahlo, Sandra Robrecht, et al.Pageof 9